MedTrace Logo

Perioperative Intravenous Lidocaine in Liver Surgery

NCT05153785 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2026-01-15

No results posted yet for this study

Summary

This is a randomized double blinded placebo-controlled study, conducted in Lund, Sweden. Patients will be randomized in two groups, with a ratio of 1:1. The experimental arm will receive intravenous Lidocaine perioperatively, and the Control arm will receive placebo, i.e. normal Saline. Postoperative both arms will get routine pain Control with PCA, Patient Controlled Analgesia with an intravenous Oxycodone-infusion. Outcome-measures will include patients pain intensity scoring, and opioid consumption.

Conditions

  • Liver Metastases
  • Liver Cancer
  • Postoperative Pain
  • Opioid Use

Interventions

DRUG

Lidocaine

Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery

DRUG

Normal saline

Placebo

Sponsors & Collaborators

  • Lund University Hospital

    lead OTHER

Principal Investigators

  • Bobby Tingstedt, Prof · Lund University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2025-06-12
Completion
2025-12-06

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153785 on ClinicalTrials.gov